keyword
MENU ▼
Read by QxMD icon Read
search

bladder small cell carcinoma

keyword
https://www.readbyqxmd.com/read/28056456/bladder-metastases-from-lung-cancer-clinical-and-pathological-implications-a-systematic-review
#1
Francesca Sanguedolce, Domenico Loizzi, Francesco Sollitto, Maurizio Di Bisceglie, Giuseppe Lucarelli, Giuseppe Carrieri, Pantaleo Bufo, Luigi Cormio
Lung cancer is the tumor with the highest incidence in males worldwide and the most common cause of death from cancer overall; its high mortality is mostly due to its propensity to spread to other organs through lymphatic and blood vessels in spite of proper treatment. Bladder metastases from lung cancer are rare, with only 11 cases having been reported, all in recent years. This review aims to discuss some critical points regarding this uncommon condition, namely: (a) lung and bladder tumors share similar etiologic features; (b) almost all bladder metastases from lung cancer arise from lung adenocarcinomas; (c) cytology and superficial bladder biopsy may be falsely negative, since the neoplastic cells coming through the hematogenous route are typically located in the lamina propria and/or muscularis propria of the bladder wall; and (d) the differential diagnosis with primary bladder adenocarcinoma as well as primary and secondary small-cell carcinomas may be challenging...
January 6, 2017: Oncology
https://www.readbyqxmd.com/read/28040422/pure-but-not-mixed-histologic-variants-are-associated-with-poor-survival-at-radical-cystectomy-in-bladder-cancer-patients
#2
Marco Moschini, Shahrokh F Shariat, Roberta Lucianò, David D'Andrea, Beat Foerster, Mohammad Abufaraj, Marco Bandini, Paolo Dell'Oglio, Rocco Damiano, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Andrea Gallina
PURPOSE: To evaluate the impact of pure and mixed histologic variant versus pure urothelial carcinoma in nonmetastatic bladder cancer (BCa) patients treated with radical cystectomy (RC). PATIENTS AND METHODS: We evaluated data from 1067 patients treated with RC and pelvic lymph node dissection between 1990 and 2013 at a single institution tertiary-care referral center. All specimens were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the impact of the presence of pure and mixed histologic variants versus pure urothelial on recurrence, cancer-specific mortality, and overall mortality after accounting for all available confounders...
December 14, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27991416/small-cell-carcinoma-of-the-bladder-20-year-single-institution-retrospective-review
#3
Kyungsuk Jung, Pooja Ghatalia, Samuel Litwin, Eric M Horwitz, Robert G Uzzo, Richard E Greenberg, Rosalia Viterbo, Daniel M Geynisman, Alexander Kutikov, Elizabeth R Plimack, Marc C Smaldone, Yu-Ning Wong, Marijo Bilusic
INTRODUCTION: Small-cell carcinoma of the bladder is a poorly differentiated neoplasm with aggressive behavior. We analyzed clinical outcomes of patients who were treated at our institution to identify an optimal treatment strategy. MATERIALS AND METHODS: Retrospective chart analysis was performed for patients who were treated for small-cell carcinoma of the bladder at Fox Chase Cancer Center between 1995 and 2015. Survival was compared between different treatment periods (before January 2010 vs...
September 30, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27979310/argininosuccinate-synthetase-1-loss-in-invasive-bladder-cancer-regulates-survival-through-general-control-nonderepressible-2-kinase-mediated-eukaryotic-initiation-factor-2%C3%AE-activity-and-is-targetable-by%C3%A2-pegylated-arginine-deiminase
#4
Divya Sahu, Sounak Gupta, Andrew M Hau, Kazufumi Nakashima, Mariah Z Leivo, Stephen C Searles, Paul Elson, John S Bomalaski, Darren E Casteel, Gerry R Boss, Donna E Hansel
Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for arginine synthesis, occurs in many cancers, making cells dependent on extracellular arginine and targetable by the arginine-degrading enzyme pegylated arginine deiminase (ADI-PEG 20). We evaluated ASS1 expression and effects of ASS1 loss in bladder cancer which, despite affecting >70,000 people in the United States annually, has limited therapies. ASS1 loss was identified in conventional and micropapillary urothelial carcinoma, small cell, and squamous cell carcinoma subtypes of invasive bladder cancer, as well as in T24, J82, and UM-UC-3 but not in 5637, RT112, and RT4 cell lines...
December 9, 2016: American Journal of Pathology
https://www.readbyqxmd.com/read/27920687/a-case-of-primary-small-cell-carcinoma-of-the-bladder
#5
Ashita Ono, Yosuke Hirasawa, Mitsumasa Yamashina, Naoto Kaburagi, Takashi Mima, Toru Sugihara, Riu Hamada, Tatsuo Gondo, Makoto Ohori, Toshitaka Nagao, Yoshio Ohno
Primary small-cell carcinoma arising from the bladder (SmCCB) is uncommon. It differs from urothelial carcinoma (UC), the most common type of bladder cancer, with respect to its cell of origin, biology, and prognosis. Biologically, prostatic SmCCB is much more aggressive than UC, and the prognosis for cases with distant metastasis is especially poor. We report here a case of primary SmCCB (cT3bN1M0) treated with radical cystectomy.
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27878946/targeted-inhibition-of-polo-like-kinase-1-by-a-novel-small-molecule-inhibitor-induces-mitotic-catastrophe-and-apoptosis-in-human-bladder-cancer-cells
#6
Zhe Zhang, Guojun Zhang, Chuize Kong
Bladder cancer is a common cancer with particularly high recurrence after transurethral resection. Despite improvements in neoadjuvant chemotherapy, the outcome of patients with advanced bladder cancer has changed very little. In this study, the anti-tumour activities of a novel Polo-like kinase 1 (PLK1) inhibitor (RO3280) was evaluated in vitro and in vivo in the bladder carcinoma cell lines 5637 and T24. MTT assays, colony-formation assays, flow cytometry, cell morphological analysis and trypan blue exclusion assays were used to examine the proliferation, cell cycle distribution and apoptosis of bladder carcinoma cells with or without RO3280 treatment...
November 23, 2016: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/27863432/e-cadherin-downregulation-sensitizes-pten-mutant-tumors-to-pi3k%C3%AE-silencing
#7
África Millán-Uclés, Susana Zuluaga, Miriam Marqués, Jesus Vallejo-Díaz, Lorena Sanz, Ariel E Cariaga-Martínez, Francisco X Real, Ana C Carrera
Alterations in phosphatidylinositol 3-kinase (PI3K) and in PTEN (phosphatase and tensin homolog), the negative regulator of the PI3K pathway, are found in nearly half of human tumors. As PI3Kβ, the main isoform activated in PTEN-mutant tumors, has kinase-dependent and -independent activities, we compared the effects of depleting vs. drug-inhibiting PI3Kβ kinase activity in a collection of diverse tumor types and in a set of bladder carcinoma cell lines grown as xenografts in mice. PI3Kβ depletion (by intratumor injection of PIK3CB siRNA) induced apoptosis and triggered regression of PTEN-mutant tumors more efficiently than PI3Kβ inhibition...
November 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27846884/future-perspectives-in-melanoma-research-meeting-report-from-the-melanoma-bridge-napoli-december-1st-4th-2015
#8
Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A Davies, Sandra Demaria, Reinhard Dummer, Alexander M Eggermont, Soldano Ferrone, Yang Xin Fu, Thomas F Gajewski, Claus Garbe, Veronica Huber, Samir Khleif, Michael Krauthammer, Roger S Lo, Giuseppe Masucci, Giuseppe Palmieri, Michael Postow, Igor Puzanov, Ann Silk, Stefani Spranger, David F Stroncek, Ahmad Tarhini, Janis M Taube, Alessandro Testori, Ena Wang, Jennifer A Wargo, Cassian Yee, Hassane Zarour, Laurence Zitvogel, Bernard A Fox, Nicola Mozzillo, Francesco M Marincola, Magdalena Thurin
The sixth "Melanoma Bridge Meeting" took place in Naples, Italy, December 1st-4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's disease...
November 15, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27801735/fading-with-time-of-pd-l1-immunoreactivity-in-non-small-cells-lung-cancer-tissues-a-methodological-study
#9
Francesca Giunchi, Alessio Degiovanni, Niccolò Daddi, Rocco Trisolini, Andrea Dell'Amore, Claudio Agostinelli, Andrea Ardizzoni, Michelangelo Fiorentino
Blockade of inhibitory immune checkpoints is currently arising as a potential immunologic option for tumor therapy. Inhibition of programmed cell death protein 1 and/or its specific ligand programmed death-ligand 1 (PD-L1) was effective in clinical trials in advanced melanoma, non-small cell lung cancer (NSCLC) bladder and kidney cancer. The predictive role of the immunohistochemical (IHC) expression of PD-L1 is highly debated. Different reagents, clones, cutoffs of cell expression and subjective interpretation of PD-L1 immunoreactivity in epithelial cells and lymphocytes are the main issue...
October 31, 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/27785426/variant-histology-in-bladder-cancer-how-it-should-change-the-management-in-non-muscle-invasive-and-muscle-invasive-disease
#10
REVIEW
Yvonne Klaile, Katrin Schlack, Martin Boegemann, Julie Steinestel, Andres Jan Schrader, Laura-Maria Krabbe
Bladder cancer (BC) is a frequent type of carcinoma with an estimated incidence of approximately 100,000 men and women each year in the European Union (EU) with an associated mortality of 30,000 of these patients. In more than 70% the disease is diagnosed in a non-muscle invasive stage with the chance of minimally invasive, local treatment only, which might be required repetitively due to high rate of recurrence. In contrast, muscle invasive or metastatic stages need multimodal treatment strategies including surgical treatment and chemotherapy (CTX) in neoadjuvant (NAC), adjuvant, or palliative settings...
October 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/27777770/safety-and-efficacy-of-anti-pd-1-in-patients-with-baseline-cardiac-renal-or-hepatic-dysfunction
#11
Bridgette A Kanz, Megan H Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia Morgans, Jeffrey A Sosman, Suthee Rapisuwon, R Martin Conry, Zeynep Eroglu, Douglas B Johnson
BACKGROUND: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not candidates for other anti-cancer therapies, highlighting their need for active treatment options. METHODS: We performed a retrospective analysis of patients from multiple centers with advanced solid tumors and baseline organ dysfunction who received anti-PD-1 therapy...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27772935/small-cell-carcinoma-of-the-bladder-report-of-two-cases
#12
Anny Setijo Rahaju, Etty Hary Kusumastuti
No abstract text is available yet for this article.
February 2016: Pathology
https://www.readbyqxmd.com/read/27698324/cytomorphologic-and-immunophenotypic-profile-of-a-cohort-of-small-cell-carcinoma-of-the-urinary-bladder
#13
Anurag Sharma, Shivani Sharma, Niharika Patnaik, Dinesh Pradhan, Kaliprasad Satapathy, Manas R Pradhan, Sambit K Mohanty
BACKGROUND: The incidence of primary small cell carcinoma (SCC) of the urinary bladder is extremely rare. We sought to analyze the cytologic and immunophenotypic features of SCC of the urinary bladder in urine and reassert the importance of cytologic examination of urine specimens for diagnosis of this tumor. METHODS: We studied the clinical and cytomorphologic features in the presurgical urine specimens (4 voided urine and 2 bladder-washing specimens) of histopathologically and immunohistochemically proven cases of SCC of the urinary bladder...
2016: Acta Cytologica
https://www.readbyqxmd.com/read/27674194/treatment-outcomes-in-limited-stage-small-cell-carcinoma-of-the-bladder
#14
O Bhattasali, C A Laqui, C N Chang-Halpenny, S Iganej, A R Rao
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27669755/fibroblast-growth-factor-receptor-fgfr-alterations-in-squamous-differentiated-bladder-cancer-a-putative-therapeutic-target-for-a-small-subgroup
#15
Philipp H Baldia, Angela Maurer, Timon Heide, Michael Rose, Robert Stoehr, Arndt Hartmann, Sarah V Williams, Margaret A Knowles, Ruth Knuechel, Nadine T Gaisa
Although drugable fibroblast growth factor receptor (FGFR) alterations in squamous cell carcinomas (SCC) of various entities are well known, little is known about FGFR modifications in squamous differentiated bladder cancer. Therefore, our study evaluated FGFR1-3 alterations as a putative therapeutic target in this subgroup. We analyzed 73 squamous differentiated bladder cancers (n = 10 pT2, n = 55 pT3, n = 8 pT4) for FGFR1-3 protein expression, FGFR1-3 copy number variations, FGFR3 chromosomal rearrangements (fluorescence in situ hybridization (FISH)) and FGFR3 mutations (SNapShot analysis)...
September 22, 2016: Oncotarget
https://www.readbyqxmd.com/read/27664399/in-silico-prediction-and-in-vitro-and-in-vivo-validation-of-acaricide-fluazuron-as-a-potential-inhibitor-of-fgfr3-and-a-candidate-anticancer-drug-for-bladder-carcinoma
#16
Kunbin Ke, Hongjian Li, Hong Yao, Xi-Nan Shi, Chao Dong, Ying Zhu, Xu Liu, Ling Li, Kwong-Sak Leung, Man-Hon Wong, Xiao-Dong Liu, Hsiang-Fu Kung, Marie Chia-Mi Lin
Bladder carcinoma (BC) is the 9(th) most common cause of cancer worldwide. Surgical resection and conventional chemotherapy and radiotherapy will ultimately fail due to tumor recurrence and resistance. Thus, the development of novel treatment is urgently needed. Fibroblast growth factor receptor 3 (FGFR3) is an important and well-established target for BC treatment. In this study, we utilized the free and open-source protein-ligand docking software idock to prospectively identify potential inhibitors of FGFR3 from 3167 worldwide approved small-molecule drugs using a repositioning strategy...
September 24, 2016: Chemical Biology & Drug Design
https://www.readbyqxmd.com/read/27592529/upstaging-of-nonurothelial-histology-in-bladder-cancer-at-the-time-of-surgical-treatment-in-the-national-cancer-data-base
#17
Andrew J Cohen, Vignesh Packiam, Charles Nottingham, Gary Steinberg, Norm D Smith, Sanjay Patel
PURPOSE: To determine patient and pathologic characteristics as well as outcomes for patients with clinically localized, nonurothelial histology bladder cancer. MATERIALS AND METHODS: Using the National Cancer Data Base, we identified patients between 2000 and 2010 diagnosed with bladder cancer as their only malignancy undergoing definitive surgical management. Patients were characterized as urothelial (n = 13,442), squamous (n = 789), small cell (n = 124), adenocarcinoma (n = 789), or other histology (n = 499)...
January 2017: Urologic Oncology
https://www.readbyqxmd.com/read/27573550/mir-194-is-a-negative-regulator-of-gef-h1-pathway-in-melanoma
#18
Bingyu Guo, Qiang Hui, Yu Zhang, Peng Chang, Kai Tao
The incidence and associated mortality of melanoma continues to increase worldwide. At present, there is no curative therapy for advanced stage of melanoma. It is necessary to find new indicators of prognosis and therapeutic targets. Increasing evidence shows that miRNA can provide potential candidate biomarkers for melanoma and therapeutic targets. GEF-H1, a regulator of RhoA, as oncogenic driver in melanoma, promotes the growth and invasion of melanoma. miR-194 is a tumor-suppressor gene in multiple tumors, such as bladder and non-small cell lung cancer, and clear cell renal cell carcinoma...
October 2016: Oncology Reports
https://www.readbyqxmd.com/read/27529044/an-extremely-rare-case-of-advanced-metastatic-small-cell-neuroendocrine-carcinoma-of-sinonasal-tract
#19
Yu Yu Thar, Poras Patel, Tiangui Huang, Elizabeth Guevara
Small cell neuroendocrine carcinoma (SNEC) is a rare form of malignancy. It mainly presents as bronchogenic neoplasm, and the extrapulmonary form accounts for only 0.1% to 0.4% of all cancers. These extrapulmonary tumors have been described most frequently in the urinary bladder, prostate, esophagus, stomach, colon and rectum, gall bladder, head and neck, cervix, and skin. Primary SNEC of the sinonasal tract is extremely rare with only less than 100 cases reported in the literature. Because of extreme rarity and aggressiveness of the tumor, the management for this entity varies considerably mandating multimodality approach...
2016: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/27495099/comparison-between-whole-mount-tissue-preparations-and-virtual-tissue-microarray-samples-for-measuring-ki-67-and-apoptosis-indices-in-human-bladder-cancer-a-cross-sectional-study
#20
Hisashi Oshiro, Bogdan A Czerniak, Kentaro Sakamaki, Koji Tsuta, Jolanta Bondaruk, Afsaneh Keyhani, Colin P Dinney, Takeshi Nagai, Ashish M Kamat
Recent tissue microarray (TMA)-based studies have shown that cell proliferation- and apoptosis-related biomarkers are associated with clinical outcomes in patients with bladder urothelial carcinoma. However, little is known about the differences in these biomarker measurements between whole mount tissue preparations and TMAs. This study aimed to elucidate the discrepancy in the measurements of Ki-67 indices (KIs) and apoptosis indices (AIs) between whole mount tissue preparations and TMAs of bladder urothelial carcinoma samples...
August 2016: Medicine (Baltimore)
keyword
keyword
68849
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"